ArticleMolecular biology reports2025
Clinical value of serum PRDM16 in early diagnosis and prognosis assessment of lung adenocarcinoma.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe PR domain-containing 16 (PRDM16) is essential for the development of cardiomyopathy and some tumors. This study aimed to verify its expression level and clinical value for lung adenocarcinoma (LUAD) early diagnosis and prognosis. METHODS AND
resultsPublic databases were searched to assess PRDM16 expression and its role in prognosis. PRDM16 expression was evaluated using real-time quantitative polymerase chain reaction, enzyme-linked immunosorbent assay, western blotting, and immunohistochemistry. We explored the relationship between PRDM16 levels and clinical characteristics. Early diagnosis and prognosis of PRDM16 alone or in conjunction with traditional tumor markers for utilizing an operating system and area under the curve (AUC). The UALCAN tool revealed low PRDM16 expression in LUAD tissues. Patients had a poorer overall survival. PRDM16 mRNA and protein levels were lower at the cellular, serum and tissues levels. Serum PRDM16 levels differed significantly between the groups in terms of tumor stage, size, and metastasis to the lymph nodes and organs. When PRDM16 was used to diagnose and assess prognosis of LUAD, the AUC reached 0.804 and 0.727, respectively. Interestingly, in predicting the early diagnosis and prognosis of LUAD, the AUC of the three markers (PRDM16, carcinoembryonic antigen, and carbohydrate antigen 125) reached 0.946 and 0.822, respectively.
conclusionsPRDM16 expression could be an effective parameter diagnosing and assessing the prognosis of LUAD. Serum PRDM16 may be a convenient way to identify LUAD, especially, when PRDM16 is combined with traditional tumor markers.
Indexed as
Identifiers
39937385What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.